{"DataElement":{"publicId":"7847797","version":"1","preferredName":"EBMT Blade Myeloma 1998 Oncology Response Criteria Status Veno-Occlusive Disease Severe Type","preferredDefinition":"The severity of Veno-Occlusive disease according to EBMT criteria.","longName":"EBMT_STAT","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7847794","version":"1","preferredName":"EBMT Blade Myeloma 1998 Oncology Response Criteria Status","preferredDefinition":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. (Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998 Sep;102(5):1115-23.)_A condition or state at a particular time.","longName":"7847792v1.0:2320064v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7847792","version":"1","preferredName":"EBMT Blade Myeloma 1998 Oncology Response Criteria","preferredDefinition":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. (Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998 Sep;102(5):1115-23.)","longName":"C126005","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EBMT Blade Myeloma 1998 Oncology Response Criteria","conceptCode":"C126005","definition":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. (Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998 Sep;102(5):1115-23.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D22C9778-DA31-4038-E053-4EBD850A1798","latestVersionIndicator":"Yes","beginDate":"2021-12-02","endDate":null,"createdBy":"LEEW","dateCreated":"2021-12-02","modifiedBy":"ONEDATA","dateModified":"2021-12-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2320064","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-037B-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D22C9778-DA3F-4038-E053-4EBD850A1798","latestVersionIndicator":"Yes","beginDate":"2021-12-02","endDate":null,"createdBy":"LEEW","dateCreated":"2021-12-02","modifiedBy":"MAESKEB","dateModified":"2022-03-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7847796","version":"1","preferredName":"Veno-Occlusive Disease Severe Type","preferredDefinition":"Disorder in which veins are partially or completely obstructed or the blood flow through the veins is suboptimal.--2004_Intensely bad or unpleasant in degree, quality or extent._Something distinguishable as an identifiable class based on common qualities.","longName":"7847796v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"500","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Very severe","valueDescription":"Very severe","ValueMeaning":{"publicId":"2573798","version":"1","preferredName":"Very severe","longName":"2573798","preferredDefinition":"Very severe","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-ED53-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-25","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-03-25","modifiedBy":"SHIDED","dateModified":"2005-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D22AEF39-E96B-4422-E053-4EBD850A0C74","beginDate":"2021-12-02","endDate":null,"createdBy":"LEEW","dateCreated":"2021-12-02","modifiedBy":"ONEDATA","dateModified":"2021-12-02","deletedIndicator":"No"},{"value":"Severe","valueDescription":"Severe","ValueMeaning":{"publicId":"7639778","version":"1","preferredName":"Severe","longName":"7639778","preferredDefinition":"Severe","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C091ABA9-680C-1D5C-E053-4EBD850ABD42","latestVersionIndicator":"Yes","beginDate":"2021-04-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-04-22","modifiedBy":"KUMMEROA","dateModified":"2021-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D22AEF39-E97F-4422-E053-4EBD850A0C74","beginDate":"2021-12-02","endDate":null,"createdBy":"LEEW","dateCreated":"2021-12-02","modifiedBy":"ONEDATA","dateModified":"2021-12-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7847795","version":"1","preferredName":"Veno-Occlusive Disease Severe Type","preferredDefinition":"Disorder in which veins are partially or completely obstructed or the blood flow through the veins is suboptimal.--2004:Intensely bad or unpleasant in degree, quality or extent.:Something distinguishable as an identifiable class based on common qualities.","longName":"C8301:C70667:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Veno-Occlusive Disease","conceptCode":"C8301","definition":"Disorder in which veins are partially or completely obstructed or the blood flow through the veins is suboptimal.--2004","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Severe","conceptCode":"C70667","definition":"Intensely bad or unpleasant in degree, quality or extent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D22AEF39-E944-4422-E053-4EBD850A0C74","latestVersionIndicator":"Yes","beginDate":"2021-12-02","endDate":null,"createdBy":"LEEW","dateCreated":"2021-12-02","modifiedBy":"ONEDATA","dateModified":"2021-12-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D22AEF39-E955-4422-E053-4EBD850A0C74","latestVersionIndicator":"Yes","beginDate":"2021-12-02","endDate":null,"createdBy":"LEEW","dateCreated":"2021-12-02","modifiedBy":"LEEW","dateModified":"2022-01-10","changeDescription":"AAML1831 - WL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"EBMT status:","type":"Preferred Question Text","description":"EBMT status:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D22D71F5-6FA0-68B9-E053-4EBD850A1A66","latestVersionIndicator":"Yes","beginDate":"2021-12-02","endDate":null,"createdBy":"LEEW","dateCreated":"2021-12-02","modifiedBy":"LEEW","dateModified":"2022-01-10","changeDescription":"AAML1831 - WL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}